These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 17233806)
1. Relevance of the prostate-specific antigen (PSA) nanotest compared to the classical PSA test in the organized mass screening of prostate cancer. Azzouzi AR; Larre S; Cormier L; Roupret M; Valeri A; Mangin P; Berthon P; Villette JM; Fiet J; Cussenot O BJU Int; 2007 Apr; 99(4):762-4. PubMed ID: 17233806 [TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer. Nanri M; Nanri K; Fujiyama C; Tokuda Y; Nakamura K; Uozumi J Int J Urol; 2007 Jun; 14(6):505-9. PubMed ID: 17593094 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of a new, rapid, qualitative, one-step PSA Test for prostate cancer screening: the PSA RapidScreen test. Miano R; Mele GO; Germani S; Bove P; Sansalone S; Pugliese PF; Micali F Prostate Cancer Prostatic Dis; 2005; 8(3):219-23. PubMed ID: 15897915 [TBL] [Abstract][Full Text] [Related]
4. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer. Chun FK; Hutterer GC; Perrotte P; Gallina A; Valiquette L; Benard F; McCormack M; Briganti A; Ionescu C; Jeldres C; Guay JP; Saad F; Karakiewicz PI BJU Int; 2007 Jul; 100(1):37-41. PubMed ID: 17488305 [TBL] [Abstract][Full Text] [Related]
5. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men. Culp S; Porter M BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868 [TBL] [Abstract][Full Text] [Related]
6. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran. Hosseini SY; Moharramzadeh M; Ghadian AR; Hooshyar H; Lashay AR; Safarinejad MR Int J Urol; 2007 May; 14(5):406-11. PubMed ID: 17511722 [TBL] [Abstract][Full Text] [Related]
8. Prostate cancer screening with prostate-specific antigen in hemodialysis patients. Horinaga M; Kitamura K; Saito S; Ukimura O; Nakanoma T; Okihara K; Kitagawa M; Nakanishi H; Miki T Urol Int; 2007; 78(4):334-7. PubMed ID: 17495492 [TBL] [Abstract][Full Text] [Related]
9. A 6-year analysis of the clinicopathological profile of patients with prostate cancer at the University Hospital of the West Indies, Jamaica. Coard KC; Skeete DH BJU Int; 2009 Jun; 103(11):1482-6. PubMed ID: 19076136 [TBL] [Abstract][Full Text] [Related]
10. Effect of ageing and body mass index on prostate-specific antigen levels among Chinese men in Singapore from a community-based study. Chia SE; Lau WK; Chin CM; Tan J; Ho SH; Lee J; Cheng C BJU Int; 2009 Jun; 103(11):1487-91. PubMed ID: 19076145 [TBL] [Abstract][Full Text] [Related]
11. Is there a role for serum human tissue kallikrein in detection of prostate cancer? Ochiai A; Shukla A; Davis JW; Fritsche HA; Bhadkamkar V; Babaian RJ Urology; 2007 Sep; 70(3):519-22. PubMed ID: 17905108 [TBL] [Abstract][Full Text] [Related]
12. [Prostate cancer and prostate specific antigen screening]. Camici M Minerva Med; 2004 Feb; 95(1):25-34. PubMed ID: 15041924 [TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. Sun L; Moul JW; Hotaling JM; Rampersaud E; Dahm P; Robertson C; Fitzsimons N; Albala D; Polascik TJ BJU Int; 2007 Apr; 99(4):753-7. PubMed ID: 17244286 [TBL] [Abstract][Full Text] [Related]
14. Point-of-care PSA testing: an evaluation of PSAwatch. Karim O; Rao A; Emberton M; Cochrane D; Partridge M; Edwards P; Walker I; Davidson I Prostate Cancer Prostatic Dis; 2007; 10(3):270-3. PubMed ID: 17353914 [TBL] [Abstract][Full Text] [Related]
15. Obesity and screening PSA levels among men undergoing an annual physical exam. Rundle A; Neugut AI Prostate; 2008 Mar; 68(4):373-80. PubMed ID: 18189231 [TBL] [Abstract][Full Text] [Related]
16. Value of prostate-specific antigen and prostate-specific antigen density in detection of prostate cancer in an Iranian population of men. Ghafoori M; Varedi P; Hosseini SJ; Asgari M; Shakiba M Urol J; 2009; 6(3):182-8. PubMed ID: 19711272 [TBL] [Abstract][Full Text] [Related]
17. Comparability of serum prostate-specific antigen measurement between the Roche Diagnostics Elecsys 2010 and the Abbott Architect i2000. Gray MA; Cooke RR; Weinstein P; Nacey JN Ann Clin Biochem; 2004 May; 41(Pt 3):207-12. PubMed ID: 15117434 [TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen kinetics in screen-detected prostate cancer in Japan. Takechi H; Ito K; Yamamoto T; Miyakubo M; Ohi M; Suzuki K Urology; 2008 Nov; 72(5):1111-5. PubMed ID: 18342926 [TBL] [Abstract][Full Text] [Related]
19. The utility of prostate-specific antigen velocity thresholds in clinical practice: a population-based analysis. Connolly D; Black A; Murray LJ; Nambirajan T; Keane PF; Gavin A BJU Int; 2008 Jun; 101(12):1507-12. PubMed ID: 18341627 [TBL] [Abstract][Full Text] [Related]
20. Ten year trend in prostate cancer screening with high prostate-specific antigen exposure rate in Japan. Okihara K; Kitamura K; Okada K; Mikami K; Ukimura O; Miki T Int J Urol; 2008 Feb; 15(2):156-60; discussion 161. PubMed ID: 18269453 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]